ライフサイエンスコーパス: hydrobromide

1 idue with N-(2-bromoethyl)-3-oxidopyridinium hydrobromide.

2 ce microscope tip coated with poly-dl-lysine hydrobromide.

3 on with 6-(bromomethyl)-2,4-pteridinediamine hydrobromide.

4 ethoxyphenyl)-1(6H)-p yridazinebutanoic acid hydrobromide]).

5 nd tested under the influence of scopolamine hydrobromide (0.2 or 0.5 mg/kg, intraperitoneal) after a

6 t with the muscarinic antagonist scopolamine hydrobromide (1.5-6 mg/kg) potentiated the response to A

7 Described here is a synthesis of 1 hydrobromide (1.HBr) employing in the key step a Viscont

8 Twelve weeks of citalopram hydrobromide (10 mg/5 mL) or placebo.

9 dropyrido[4',3':4,5]furo[2, 3-d]pyrimidine-7-hydrobromide (16).

10 ation of the antimuscarinic drug scopolamine hydrobromide (4 microg/kg intravenously) compared with p

11 ravenous infusions of placebo or scopolamine hydrobromide (4 microg/kg).

12 +/-)-8-hydroxy-2-di-(n-propylamino) tetralin hydrobromide; 5-HT(1A) agonist; in vivo] reduced respira

13 injection of 25 microg of 6-hydroxydopamine hydrobromide (6-OHDA) midway between the two implant sit

14 o to treatment with either tebipenem pivoxil hydrobromide (600 mg orally every 8 h) or amoxicillin-cl

15 mino-8-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide (8-OH-DPAT) (10 nmol), when microinjected b

16 onist 8-hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT) was inhibited completely by per

17 (+/-)8-hydroxy-2-(di-N-propylamino)tetrealin hydrobromide (8-OH-DPAT).

18 agonist, (+)-8-hydroxy-dipropylaminotetralin hydrobromide (8-OHDPAT) (50 pmol, 2.0 and 3.0 nmol), int

19 binofuranosyl) pyrrolo[2,3-d]pyridazin-7-one hydrobromide (9).

20 rturbations caused by oral tebipenem pivoxil hydrobromide (a novel carbapenem) and by amoxicillin-cla

21 withdrawal and concomitant use of citalopram hydrobromide, a phenomenon that has been rarely reported

22 fied with (2-aminoethyl)methanethiosulfonate hydrobromide, a reagent that restores positive charge at

23 Moreover, we identified arecoline hydrobromide (AH) as a covalent ACAT1 inhibitor that bin

24 ate nasal spray and zolmitriptan, eletriptan hydrobromide, almotriptan malate, and rizatriptan benzoa

25 3-hydroxy-5-methylisoxazole-4-propionic acid hydrobromide (AMPA) interact additively to evoke [3H]ACh

26 3-hydroxy-5-methylisoxazole-4-propionic acid hydrobromide (AMPA) receptor function at endogenously ac

27 MMP-13 expression was inhibited by CCT031374 hydrobromide, an inhibitor of the canonical Wnt/beta-cat

28 at population who received tebipenem pivoxil hydrobromide and 93.6% of patients who received ertapene

29 % of patients who received tebipenem pivoxil hydrobromide and in 25.6% of patients who received ertap

30 ass were synthesized starting from arecoline hydrobromide and obtained in optically pure form through

31 mino-7-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide and PD 168,077 maleate did not produce such

32 loro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine hydrobromide) and the D2-like agonist quinelorane both f

33 ety of orally administered tebipenem pivoxil hydrobromide as compared with intravenous ertapenem in p

34 de, paroxetine hydrochloride, and citalopram hydrobromide), as reported by participants interviewed b

35 ients (58.8%) who received tebipenem pivoxil hydrobromide, as compared with 258 of 419 patients (61.6

36 1:1 ratio, to receive oral tebipenem pivoxil hydrobromide (at a dose of 600 mg every 8 hours) or intr

37 the linker bromoacetyl hydrazinonicotinamide hydrobromide (BAHNH) conjugated site specifically at pro

38 ,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide, binds less to the mGlu2 promoter in fronta

39 c interneurons via dihydro-beta-erythroidine hydrobromide (DHbetaE)-insensitive nicotinic receptors.

40 ino-8-hydroxy-1,2,3, 4-tetrahydronaphthalene hydrobromide (DPAT), with an EC(50) of approximately 10

41 +/-)-8-hydroxy-2-(di-n-propylamino)tetralin) hydrobromide] (DPAT), which acts on autoreceptors and in

42 hloride, bupropion hydrochloride, citalopram hydrobromide, duloxetine hydrochloride, escitalopram oxa

43 ed by solvent precipitation of triethylamine hydrobromide, enabled their regiospecific ring-opening a

44 NTS: Randomized clinical trial of citalopram hydrobromide for children and adolescents with autism sp

45 ry were subsequently treated with citalopram hydrobromide for up to 12 weeks.

46 p (day 4, p=0.030) and the tebipenem pivoxil hydrobromide group (days 4-10, p<0.0001) compared with b

47 assigned: 15 (50%) to the tebipenem pivoxil hydrobromide group and 15 (50%) to the amoxicillin-clavu

48 ays 4-10, p<=0.030) in the tebipenem pivoxil hydrobromide group.

49 ys 4-14 (p<=0.0019) in the tebipenem pivoxil hydrobromide group.

50 oxetine hydrochloride initiation: citalopram hydrobromide, hazard ratio = 1.00 (95% confidence interv

51 or cells (hNPCs) and found that hippeastrine hydrobromide (HH) and amodiaquine dihydrochloride dihydr

52 dec-1-ylmethyl]amino)-1-pentanaminiumbromide hydrobromide (IEM-1460), a calcium-permeable AMPA recept

53 of this series were prepared from arecoline hydrobromide in optically pure form and were evaluated f

54 Tebipenem pivoxil hydrobromide is an orally bioavailable carbapenem with a

55 ivatives ((2-aminoethyl)methanethiosulfonate hydrobromide (MTSEA) and [(2-(trimethylammonium)ethyl]me

56 2-(Aminoethyl)methanethiosulfonate hydrobromide (MTSEA) failed to inhibit serotonin transpo

57 d inside 2-(aminoethyl)-methanethiosulfonate hydrobromide (MTSEA) Further study of those mutants show

58 e reagent 2-(aminoethyl)methanethiosulfonate hydrobromide (MTSEA) in membrane preparations from trans

59 of 2.5 mM 2-aminoethyl methanethiosulfonate hydrobromide (MTSEA) or 1 mM [2-(trimethylammonium) ethy

60 2-(Aminoethyl)-methanethiosulfonate hydrobromide (MTSEA)-biotin labeled A116C and Y136C but

61 AT), 25 ng (5-aminomethyl-3-hydroxyisoxazole)hydrobromide (muscimol), 10 ng bicuculline or a combinat

62 (-)-2,10,11-trihydroxy-N-propyl-noraporphine hydrobromide (NPA) also causes translocation of delta an

63 st 2,10,11-trihydroxy-N-propylnorapomorphine hydrobromide (NPA) involve both epsilon protein kinase C

64 The impact of tebipenem pivoxil hydrobromide on the gut microbiome was similar to that o

65 to evaluate the effect of tebipenem pivoxil hydrobromide on the human gut microbiota.

66 ation to another antipsychotic or citalopram hydrobromide or open treatment over 9 months.

67 mino-7-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide, or PD 168,077 maleate (D(2)-like, D(2), D(

68 onsisting of the polypeptide, poly(l-lysine) hydrobromide, poly(l-lysine) and the polymeric dipeptide

69 (+/-)-8-hydroxy-2-(di-N-propylamino)tetralin hydrobromide rapidly stimulated proton efflux that was b

70 l-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide] reversed AMPAR responsiveness in cocaine w

71 The products, in their hydrobromide salt form, could be conveniently isolated a

72 ingle-crystal X-ray diffraction study of the hydrobromide salt.

73 tive crystallization to form a corresponding hydrobromide salt.

74 tive crystallization to form a corresponding hydrobromide salt.

75 n efficient synthesis of S-allyl thioimidate hydrobromide salts via coupling of thioamides with allyl

76 ubcutaneous injections of either scopolamine hydrobromide (SCOP; 0.5 mg/0.2 mL) or saline (SAL) four

77 hydrate-resistant, dihydro-beta-erythroidine hydrobromide-sensitive nicotinic currents elicited by 3-

78 3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrobromide] significantly increased EPSC amplitude, wh

79 The D1 receptor agonist chloro-APB hydrobromide (SKF 82958) was rewarding in morphine-depen

80 2,3,4,5-tetrahydro-1-phenyl-1H-3-benzazepine hydrobromide (SKF81297) (1-10 microm) nor the D2-like ag

81 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF81297) altered EphA5, EphrinA1, EphrinA

82 4-methoxyphenyl)pyridazin-1-yl]butanoic acid hydrobromide (SR-95531; antagonist), pentobarbital (allo

83 ,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide (TCB-2) enhanced C-fiber-evoked dorsal horn

84 ,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide (TCB-2).

85 The mean (SD) maximum dosage of citalopram hydrobromide was 16.5 (6.5) mg/d by mouth (maximum, 20 m

86 Oral tebipenem pivoxil hydrobromide was noninferior to intravenous ertapenem in

87 7-dihydroxy-1, 2, 3, 4-tetrahydronaphthalene hydrobromide) were injected intraocularly.